Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunnar Aus

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Scandinavian Journal of Urology and Nephrology|April 9, 2009
Long-term follow-up after triple treatment of prostate cancer stage pT3Sonny Schelin, Mikael Madsen, Elisabeth Palmqvist, et al.
Scandinavian Journal of Urology and Nephrology|November 5, 2003
Radical prostatectomy--long-term oncological outcome from a community hospitalMaria Tol-Fakkar, Carl Gustaf Hermansson, Jonas Hugosson, et al.
Scandinavian Journal of Urology and Nephrology|June 19, 2004
Single-dose orally administered quinolone appears to be sufficient antibiotic prophylaxis for radical retropubic prostatectomyJohan Stranne, Gunnar Aus, Christina Hansson, et al.
Urology|August 2, 2003
Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infectionBjörn Zackrisson, Peter Ulleryd, Gunnar Aus, et al.
The Journal of Urology|April 11, 2003
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curableJonas Hugosson, Gunnar Aus, Hans Lilja, et al.
Scandinavian Journal of Urology and Nephrology|December 17, 2003
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)Gunnar Aus, Charlotte Becker, Hans Lilja, et al.
Archives of Internal Medicine|September 15, 2005
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based studyGunnar Aus, Jan-Erik Damber, Ali Khatami, et al.
European Urology|April 2, 2003
Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screeningBjörn Zackrisson, Gunnar Aus, Hans Lilja, et al.
Scandinavian Journal of Urology and Nephrology|April 25, 2007
Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factorsDavid Robinson, Gunnar Aus, Julia Bak, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2010
The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trialSigrid Carlsson, Gunnar Aus, Svante Bergdahl, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Scandinavian Journal of Urology and Nephrology|April 9, 2009
Long-term follow-up after triple treatment of prostate cancer stage pT3Sonny Schelin, Mikael Madsen, Elisabeth Palmqvist, et al.
Scandinavian Journal of Urology and Nephrology|November 5, 2003
Radical prostatectomy--long-term oncological outcome from a community hospitalMaria Tol-Fakkar, Carl Gustaf Hermansson, Jonas Hugosson, et al.
Scandinavian Journal of Urology and Nephrology|June 19, 2004
Single-dose orally administered quinolone appears to be sufficient antibiotic prophylaxis for radical retropubic prostatectomyJohan Stranne, Gunnar Aus, Christina Hansson, et al.
Urology|August 2, 2003
Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infectionBjörn Zackrisson, Peter Ulleryd, Gunnar Aus, et al.
The Journal of Urology|April 11, 2003
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curableJonas Hugosson, Gunnar Aus, Hans Lilja, et al.
Scandinavian Journal of Urology and Nephrology|December 17, 2003
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)Gunnar Aus, Charlotte Becker, Hans Lilja, et al.
Archives of Internal Medicine|September 15, 2005
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based studyGunnar Aus, Jan-Erik Damber, Ali Khatami, et al.
European Urology|April 2, 2003
Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screeningBjörn Zackrisson, Gunnar Aus, Hans Lilja, et al.
Scandinavian Journal of Urology and Nephrology|April 25, 2007
Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factorsDavid Robinson, Gunnar Aus, Julia Bak, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2010
The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trialSigrid Carlsson, Gunnar Aus, Svante Bergdahl, et al.
Pageof 7